|
KMID : 1216720100020010011
|
|
Korean Journal of Gynecologic Endocrinology
2010 Volume.2 No. 1 p.11 ~ p.17
|
|
|
Hormone Therapy in Gynecologic Cancer Survivors
|
|
Kim Sang-Wook
Kim Jin-Ju
Ku Seung-Yup
|
|
|
Abstract
|
|
|
As the length of survival in patients with gynecological malignancies increases due to advances in early diagnosis
and therapy, these women frequently suffer symptoms following an iatrogenic menopause. Thus, the quality of life
becomes a major issue for the survivors. Because estrogen is a well-recognized etiologic factor of cancers such as
breast or endometrium, most physicians are probably reluctant to provide a hormonal therapy, or limit its use to only
a selected group of gynecologic cancer patients. The most recent two prospective studies did not find an increase
in the recurrence rates in endometrial cancer patients who used hormonal therapy, thus hormonal therapy after endometrial cancer treatment does not appear to have an adverse effect on endometrial cancer prognosis. Little information is available concerning the impact of hormonal therapy on the clinical outcomes of patients previously
treated for ovarian cancer, but on the basis of the currently available studies, hormonal therapy in patients with ovarian
cancer may not cause detrimental effect on overall or disease-free survival. In addition, there are no data showing
an association between poorer outcome and hormonal therapy in patients with cervical or vulvar cancers.
Nevertheless, because of a limitation of data, the physicians should thoroughly consider all possible benefits and theoretical risks of recurrence or mortality in each individual to provide the best of care for their patients. Hormonal
therapy can be considered in symptomatic patients with gynecologic cancer, after weighing the benefits against the
risk of recurrence.
|
|
|
KEYWORD
|
|
|
Gynecologic cancer, Hormonal therapy, Menopausal symptoms
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|